|
April 2, 2003, Mountain View, California - SurroMed, Inc. today
announced that it has entered into a biomarker discovery agreement
with Wyeth (NYSE: WYE). Under the terms of the agreement, Wyeth will
supply clinical samples for analysis in SurroMed's Biomarker Discovery
Laboratory. SurroMed will analyze the samples using its SurroScan™
microvolume laser-scanning cytometry system. Financial terms of the
agreement were not disclosed.
"We are delighted to apply our proprietary SurroScan cytometry
technology in this effort with Wyeth," says Nancy Grove, MD, Vice
President of Biomarker Discovery Services of SurroMed. "Our microvolume
laser scanning cytometry system analyzes and profiles hundreds of different
cell populations and cell-surface markers in small volumes of whole blood
and other biofluids. The data is analyzed and mined using SurroMed's
suite of informatics tools."
Biomarker analysis and profiling has multiple applications across all
stages of the drug discovery and development continuum from preclinical
analysis of animal samples to follow-up evaluation of patients already
receiving marketed products. SurroMed has previously announced biomarker
discovery agreements with Eli Lilly & Company, InterMune, PPD Discovery
and the MIND Institute. These agreements have included SurroScan cytometry
analysis and/or mass spectrometry based proteomic and metabolite profiling.
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed is pioneering
biomarker enabled drug discovery and development. The company focuses
on discovering and applying biomarkers to improve the drug discovery
and development process and enable the precise diagnosis and personalized
treatment of disease. SurroMed's research process yields biological
markers and information that enable accelerated, cost-efficient discovery
and development of new therapeutic products, as well as development of
diagnostic tests for early disease detection, disease staging, patient
stratification, and guiding and monitoring therapy.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Ian McConnell, Ph.D
Senior Account Executive
(415) 677-4455 ext. 233
email: [email protected]
|
